Key result
High-dose (300-325 mg) aspirin in patients with diabetes was associated with significantly fewer MACEs (HR 0.49; 95% CI 0.34-0.63; P<0.0001), regardless of ticagrelor or clopidogrel assignment.
Why the study?
Does high-dose aspirin (300-325 mg) worsen cardiovascular outcomes when used with ticagrelor in patients with diabetes?
Observational
Does high-dose aspirin (300-325 mg) worsen cardiovascular outcomes when used with ticagrelor in patients with diabetes?
Hazard Ratio: 0.49 (95% CI 0.34–0.63)
p-value: p=<0.0001
The FDA black box warning against using maintenance aspirin doses >100 mg with ticagrelor may be inappropriate and not evidence-based for patients with diabetes.
No takes yet. Share an insight, caveat, or question.
May warrant reconsideration of ticagrelor aspirin restrictions in diabetes; leaves open confirmation in prospective trials.
DiNicolantonio et al. (2013) conducted an observational in Diabetes. High-dose aspirin was evaluated on Major adverse cardiovascular events (MACEs) (HR 0.49, 95% CI 0.34-0.63, p=<0.0001). High-dose (300-325 mg) aspirin in patients with diabetes was associated with significantly fewer MACEs (HR 0.49; 95% CI 0.34-0.63; P<0.0001), regardless of ticagrelor or clopidogrel assignment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: